CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to IPSEY

rhIGF-1 (mecasermin) for a period of 86 weeks

Phase 3
Ipsen Biopharmaceuticals, Inc. (IPSEY)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Insulin-Like Growth Factor-1 Deficiency

View Full Landscape
Drug Information

Target Indication

Insulin-Like Growth Factor-1 Deficiency

Clinical Trial

NCT00125190

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.